Pfizer wins one, loses one on Prempro; J&J cuts max dosage of Tylenol;

@FiercePharma: Yervoy hits the market with $95M bang. Story | Follow @FiercePharma

> A West Virginia jury ruled for Pfizer in a Prempro lawsuit, rejecting allegations that the menopause drug caused a woman's breast cancer. Report

> Nevada's Supreme Court revived the state's deceptive trade practices lawsuit against Pfizer and two of its units, reinstating claims that the companies overstated the benefits of hormone-replacement drugs. Report

> Lupin signed on to market Eli Lilly's diabetes drugs, including the Huminsulin product range, in India and Nepal. Report

> Johnson & Johnson lowered the maximum recommended dose of Tylenol to help prevent overdoses and liver damage. Report

> GlaxoSmithKline CEO Andrew Witty pledged more hiring in U.K., thanks to recent tax-law changes. Report

> Matrix called Shire's Q2 results "outstanding" and reiterated its buy rating on the stock. Report

> PDL BioPharma saw second-quarter profits rise 40% to $70 million after it resolved a patent dispute with Novartis. Report

> Goldshield Pharmaceuticals is recalling a batch of Venaxx XL capsules because the patient information leaflet was left out of packages. Report

> Prescriptions grew by more than two-thirds in England over the last decade, with the average number dispensed per capita rising to 17.8 from 11.2. Report

> McKesson beat expectations with earnings of $1.27 per share, helped by a 9% rise in drug-distribution revenue. Report

Biotech News

@FierceBiotech: Baxter sets up $200M venture arm for early-stage investments. Item | Follow @FierceBiotech

@JohnCFierce: Merck is killing telcagepant, its migraine drug, after Ph3 data analysis. News | Follow @JohnCFierce

@RyanMFierce: More Biogen coverage to come after trip to Boston, but first catching up on pipeline priorities: Story | Follow @RyanMFierce

@MaureenFierce: New drugs trump mammograms for fewer cancer deaths. Article  | Follow @MaureenFierce

> After the R&D shakeout, Biogen aims to beef up drug pipeline. Story

> Amgen sees 26% jump in R&D spending. Article

> BDO: Biotechs continue to rein on R&D costs, focus on top prospects. Report

> FDA refuses to file Eisai app for new epilepsy drug. More

> Merck kills PhIII migraine drug program. Piece

> UK Scientists mount pioneering stem cell trial for MS. News

And Finally... A Tufts University psychiatry prof posits that the world's greatest leaders had mood disorders. Article

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.